Novonesis and Novo Nordisk will explore new solutions to improve metabolic health

Core Insights - Novonesis and Novo Nordisk have formed a research collaboration focused on the gut microbiome's role in metabolic health and well-being [1][2] - The partnership aims to develop synbiotic food supplements to improve health parameters related to metabolic health, such as blood glucose and cholesterol levels [2][3] - The collaboration will also investigate the potential of the gut microbiome to monitor and predict health trajectories and explore novel biomarkers for measuring the effectiveness of microbiome solutions [3] Company Overview - Novonesis is a leader in biosolutions, leveraging microbiology to create value across more than 30 industries, employing around 10,000 people globally [8] - Novo Nordisk, founded in 1923, is a global healthcare company focused on chronic diseases, employing approximately 78,400 people and marketing products in around 170 countries [9] Industry Context - Obesity is recognized as a chronic disease by the World Health Organization, associated with over 200 health complications, including type 2 diabetes and cardiovascular disease [5] - The role of the gut microbiome in maintaining metabolic health is increasingly acknowledged, with a focus on preventing obesity through innovative partnerships and solutions [6][7]